Core Viewpoint - Analysts expect Eli Lilly (LLY) to report quarterly earnings of $5.61 per share, reflecting a year-over-year increase of 43.1%, with revenues projected at $14.75 billion, up 30.5% from the previous year [1] Earnings Projections - The consensus EPS estimate has been revised downward by 1.5% in the past 30 days, indicating a reassessment by analysts [1][2] Key Metrics Forecast - Analysts predict 'Net Sales- Cyramza' at $246.20 million, a decrease of 1.1% year-over-year [4] - 'Net Sales- Humulin' is expected to be $206.10 million, down 7.8% year-over-year [4] - 'Net Sales- Humalog' is projected at $609.52 million, reflecting a decline of 3.5% from the previous year [4] - 'Net Sales- Forteo' is estimated at $62.76 million, down 10.2% year-over-year [5] - 'Net Sales- International-Forteo' is forecasted at $34.28 million, a decrease of 11% [5] - 'Net Sales- Cyramza (ROW)' is expected to reach $130.32 million, down 1.9% year-over-year [6] - 'Net Sales- Emgality (ROW)' is projected at $42.01 million, indicating a significant decline of 22.8% [6] - 'Net Sales- International-Alimta' is estimated at $17.05 million, down 20.3% from the previous year [6] - 'Net Sales- US-Humulin' is expected to be $154.98 million, down 8.5% year-over-year [7] - 'Net Sales- Emgality (US)' is projected at $135.67 million, reflecting a decrease of 1.4% [7] - 'Net Sales- US-Humalog' is estimated at $412.17 million, down 5.2% year-over-year [7] - 'Net Sales- US-Forteo' is expected to reach $28.73 million, indicating a decline of 8.8% [8] Stock Performance - Over the past month, shares of Lilly have returned -2.4%, contrasting with the Zacks S&P 500 composite's +0.6% change [8]
Insights Into Lilly (LLY) Q2: Wall Street Projections for Key Metrics